Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb

References

• Lionberger R, Jiang W, Huang SM, Geba G. Confidence in generic drug substitution. Clin Pharmacol Ther 2013;94:938–940
   Google Scholar
• WHO Technical Report Series No. 937: Annex 7 (pdf) WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fortieth Report (WHO Technical Report Series No. 937): Annex 7 – Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability, May 2006. htpp://www.whqlibdoc.who.int/trs/who_trs_937_eng.pdf [last accessed 15 June 2008]
   Google Scholar
• Jeong Y-H, Koh J-S, Kang M-K, Ahn Y-J, Kim I-S, Park Y, Hwang SJ, Kwak CH, Hwang JY. The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: Results of the ACCEL-GENERIC Study. Korean J Intern Med 2010;25:154–161
   PubMedGoogle Scholar
• Sambu N, Radhakrishnan A, Curzen N. A randomized crossover study comparing the antiplatelet effect of plavix versus generic clopidogrel. J Cardiovasc Pharmacol 2012;60:495–501
   Google Scholar
• Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart A, Choudhry NK, Shrank WH. Clinical equivalence of generic and brand name drugs used in cardiovascular disease: A systematic review and meta-analysis. JAMA 2008;300:2514–2526
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: The PEGASUS-PCI study. J Thromb Haemost 2012;10:529–542
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G, Gouya G, Ruzicka K, Podczeck-Schweighofer A, Christ G. Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study. Int J Cardiol 2013; 167:2018–2023
   PubMed Web of Science ®Google Scholar
• Harrison P. Advances in the monitoring of anti-P2Y12 therapy. Platelets 2012;23:510–525
   PubMed Web of Science ®Google Scholar
• Neubauer H, Krüger JC, Lasak S, Endres HG, Pepinghege F, Engelhardt A, Bulut D, Mügge A. Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: A crossover study. Clin Res Cardiol 2009;98:533–540
   PubMedGoogle Scholar
• Kaur P, Chaurasia CS, Davit BM, Conner DP. Bioequivalence study designs for generic solid oral anticancer drug products: Scientific and regulatory considerations. J Clin Pharmacol 2013;53:1252–1260
   Google Scholar
• Oberhaensli M, Lehner C, Puricel S, Lehmann S, Togni M, Stauffer J-C, Baeriswyl G, Goy JJ, Cook S. A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: The CLO-CLO trial. Arch Cardiovasc Dis 2012;105:587–592
   Google Scholar
• Kim SD, Kang W, Lee H, Park DJ, Ahn JH, Kim MJ, Kim EY, Kim SW, Nam HS, Na HJ, et al. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: A randomized, open-label, crossover study in health Korean Male subjects. Clin Ther 2009;31:793–803
   PubMed Web of Science ®Google Scholar
• Borsiczky B, Sarszegi Z, Konyi A, Szabados S, Gaszner B. The effect of clopidogrel besylate and clopidogrel hydrogensulfate on platelet aggregation in patients with coronary artery disease: A retrospective study. Thromb Res 2012;129:700--703
   Google Scholar
• Siller-Matula JM, Trenk D, Schroer K, Gawaz M, Kristensen SD, Storey RF, Huber K. Response variability to P2Y12 receptor inhibitors: Expectations and reality. JACC Cardiovasc Interv 2013;6:1111–1128
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marucci R, Blindt R, Angiolillo D, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2012;56:919–1033
   Google Scholar
• Fuentes E, Fuentes F, Andrés V, Pello OM, Font de Mora J, Palomo I. Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis. Platelets 2013;24:255–262
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Delle-Karth G, Christ G, Neunteufl T, Maurer G, Huber K, Tolios A, Drucker C, Jilma B. Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. Int J Cardiol 2013;167:430–435
   Google Scholar
• Manigacapra F, Peace A, Barbato E, Patti G, Gatto L, Ricottini E, De Bruyne B, Di Sciascio G, Wijns W. Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. Platelets 2013. [Epub ahead of print]
   Google Scholar
• Drepper MD, Spahr L, Frossard JL. Clopidogrel and proton pump inhibitors – Where do we stand in 2012? World J Gastroenterol 2012;18:2161–2171
   PubMed Web of Science ®Google Scholar
• Yin T, Miyata T. Pharmacogenomics of clopidogrel: Evidence and perspectives. Thromb Res 2011;128:307–316
   PubMed Web of Science ®Google Scholar
• Abdel-Latif A, Smyth S. Preventing platelet thrombosis with a PAR1 pepducin. Circulation 2012;126:13–15
   Google Scholar
• Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166–1173
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: A pharmacodynamic study. J Am Coll Cardiol 2012;60:193–199
   PubMed Web of Science ®Google Scholar
• Jeong Y-H, Kim I-S, Park Y, Kang MK, Koh JS, Hwang SJ, Kwak CH, Hwang JY. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance- dose clopidogrel of 150 mg/day: Results of the ACCEL DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. JACC Cardiovasc Interv 2010;3:731–741
   PubMed Web of Science ®Google Scholar
• Pena A, Collet JP, Hulot JS, Silvain J, Barthélémy O, Beygui F, Funck-Brentano C, Montalescot G. Can we overridden clopidogrel resistance? Circulation 2009;119:2854–2857
   PubMed Web of Science ®Google Scholar
• Dridi NP, Johansson PI, Clemmensen P, Stissing T, Radu MD, Quayyum A, Pedersen F, Helqvist S, Saunamäki K, Kelbæk H, et al. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response – The TAILOR (Thrombocytes and Individualization of Oral antiplatelet therapy in percutaneous coronary intervention) randomized trial. Platelets 2013. [Epub ahead of print]
   Google Scholar
• Teng R, Maya J, Butler K. Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers. Platelets 2013;24:615–624
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246–251
   PubMed Web of Science ®Google Scholar
• Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, Lau WC, McLaughlin TJ, Frelinger AL. Evidence that preexistent variability in platelet response to ADP accounts for ‘clopidogrel resistance’. J Thromb Haemost 2007;5:75–81
   PubMed Web of Science ®Google Scholar